The latest development could significantly reshape India’s cardiac drugs market
Until now, infants were treated with medications intended for older children, which posed a risk of overdose because babies metabolize drugs differently due to their immature liver function
The first order impact will be a slow market share gain from innovators after a generic launch
Divi's Labs has a CDMO contract with Novartis for Entresto
The total value of the deal is likely to be around Rs 2,000 crore, the channel said
It expects its 2024 net sales to grow by a high-single to low double-digit percentage with adjusted operating income growing by a low double-digit to mid-teens percentage, Novartis said in a statement.
Novartis India, a listed entity, is set to undergo an assessment encompassing various aspects, including its parent Novartis AG's 70.68% shareholding.
MorphoSys secured pelabresib, with a $1.7 billion takeover from U.S. cancer specialist Constellation Pharma, in the hopes of setting a new treatment standard.
From Chinese regulator's new restrictions and Bank of Japan's plans to shift gears to Invitae's bankruptcy woes and Novartis' mega acquisition bid,here's a look at some of the major developments from across the world.
As per IQVIA, MAT September, 2023 data, sales for these brands was at Rs 207.8 Crores.
"We are looking at new therapies of cell therapy, radioisotopes for cancer treatment. 20 percent of our revenue goes as investment towards cancer treatment. We have 30 compounds in the pipeline towards treatment of cancer," Novartis India MD Amitabh Dube said.
Challenge for 2024: The Novartis India country president and MD will prioritise personal health and wellness. And embrace FOMO, making peace with the fact that one can't always be in the know.
The transaction, in the form of a merger of a newly formed Novartis subsidiary and Chinook, is expected to close in the second half of 2023, the Swiss drugmaker said in a statement.
The industry body says it is collaborating, converging and co-creating with the government and other stakeholders to enable an innovative environment in India
The Mumbai-based company has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) to manufacture and market Galvus and Galvus combination brands, it said in a regulatory filing.
The Swiss company said it will buy a maximum of 10% of its own stock over the period from its last Annual General Meeting, which took place on March 7, up to the AGM in 2026.
The Kerala High Court said the drugmakers are parties to a petition seeking generic versions of their patented products to lower treatment costs.
Novartis’ global CEO Vas Narasimhan finds solace in his Indian heritage when he has to gather the courage to make a tough decision in life, even on a professional level. Catch this exclusive conversation between Novartis CEO Vas Narasimhan and CNBC-TV18's managing editor Shereen Bhan to find out why he appreciates his grandparents for teaching him yoga and what he thinks about the increasing number of Indian-origin CEOs.
Vasant Narasimhan, the Indian-origin CEO of pharmaceutical giant Novartis, credits yoga and meditation for giving him courage and strength in tough times
In an exclusive interview with CNBC-TV18, Novartis top boss Vas Narasimhan spoke about the rise and rise of Indian-origin CEOs.
These diseases are prevalent in India and other developing countries, and Novartis sees a significant market opportunity in providing innovative treatments, Narasimhan said.
With a blockbuster heart failure drug Vymada going off-patent this month, its much cheaper generic versions by a number of drug makers are set to hit the market in India and several other countries.
The drug by Glenmark, under the brand name Sacu VTM, has been priced at Rs 19 per tablet for a dose of 50mg , Rs 35 per tablet for a dose of 100mg and Rs 45 per tablet for a dose of 200mg
Novartis had asked the justices to suspend a lower court's ruling that lifted a ban on generic versions of Gilenya, the Switzerland-based company's third highest-selling drug last year with $2.8 billion in sales.
Novartis (NOVN.S) announced on Thursday that it intended to spin off its generics division Sandoz in order to narrow its focus on its patented prescription drugs.